A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
NCT00281632
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Peritoneal Cancer
Ovarian Cancer
Neoplasms, Ovarian
Fallopian Tube Cancer
Interventions
DRUG:
GW786034
Sponsor
GlaxoSmithKline